The latest medicine to treat schizophrenia. How does it work and what are its side effects?

The US Food and Drug Administration (FDA) has agreed to a new remedy to treat schizophrenia in adults, which comes in the form of oral capsules, named: Cobenfy. The trait is described as the first anti -psychococcio to treat schizophrenia, which targets choline receptors instead of dopamine receptors, which is the criterion for a long time, according to the American Food and Drug Administration website. According to the World Health Organization, schizophrenia affects nearly 24 million people, or 1 in 300 people (0.32%) worldwide. Although the disease is not like many other mental disorders, it is related to a group of serious symptoms, serious weakness in personal, family, social, educational, professional and others. Schizophrenia often occurs in late adolescence and twenties, and the appearance of the disease tends to occur early in men compared to women, and the causes of schizophrenia are not known, nor is there a cure for schizophrenia, despite the presence of medication that can help the condition. Since the first antipsychotic agent is provided in the fifties of the twentieth century, subsequent medication to treat psychosis work on the same chemical that helps the brain communicate with the rest of the body: dopamine. Dopamine is a neurotransmitter that is usually related to reward and learning, but in reality it has many functions. It also plays a role in controlling movement, but Cobenfy works on another substance, which is the choline, which is responsible for organizing very nervous and muscle functions, depending on the neurotransmitter of acetylcholine. How does the new schizophrenia work? The new medication for schizophrenia targets, especially the Mascers receptors, found in the central nervous system, and involved in regulating spiritual processes, such as memory and attention. And if associated with these receptors, it stimulates choline -like effects, which increase nerve communication, and it makes it a potential medicine to treat diseases such as schizophrenia, as the choline system has a roll of defects. It also simulates the consequences of this nerve carrier in the central nervous system, which improves the positive symptoms of hallucinogenic and disorganized thinking and negative social isolation and indifference to schizophrenia to focus on stimulating the masks’ receptors. Cobenfy, also known as “Car XT”, was developed by the Carona Thurabix Company, which was bought last year by Bristol Maires Squeb for $ 14 billion, which has been the first new category of psychological disorder treatment since the approval of Kluzapin, the first unnecessary antipyre, in 1989. And “Zanomelin” is one of the medicines that began to treat Alzheimer’s and schizheimers in the early 1990s, as this remedy works as a stimulant for receptors in the brain. At that time, Elie Lily tried to develop the drug as a treatment for Alzheimer’s disease, but the side effects of the digestive system were very difficult, despite the positive results that this remedy showed in improving schizophrenia symptoms, research was discontinued due to the serious side effects caused by the activation of cholin receptors in the Peripheral Nevel. Choline receptors are a group of protein on the surface of neurons, and other cells in the body, and play an important role in transferring nerves signals. Although the development of ‘Zanomelen’ drugs has been stopped for a while, over the past few years has been a new exploration of the drug with the participation of another remedy, ‘Trusses’, which works as an anti -coordinated coordinated receptor. “Truspium” helps reduce the peripheral side effects of “adultery”, such as extreme sweat, excess saliva and diarrhea, which restores the hope for using schizophrenia. The mechanism of “Zanomelin” action is based on its effect on choline receptors in the brain, especially in the areas responsible for controlling perception and feelings such as the coffee system and the cerebral cortex. Reducing the symptoms of schizophrenia and during an early stage of research, the researchers experienced problems with ‘adultery’; Due to the peripheral side effects such as sweating, saliva and diarrhea, but with the addition of the medicine “Truspium”, which reduces these symptoms, it was reconsidered in new clinical trials, and in one of the random clinical trials, the results showed that the use of “Zanomelin” was effective with a foyiny “to improve skiofrenia. Clinical experiment showed that two patients between the ages of 18 and 60, that “Zanomelin” with “Truspium” managed to reduce the total points of the positive and negative symptoms of the schizophrenia with -17.4 compared to -5.9 of the imaginary drug. Price of 1850 dollars per month, a price approaching other schizophrenia treatments. Although the elastic dose system is used in clinical trials, its application can be complicated in the realistic world, or describe the medicine individually or as part of the mixture of fixed doses. Side effects of the drug The clinical trials showed the presence of a group of side effects of the drug; Like constipation, dry mouth and drowsiness, which are consequences that may not be acceptable in some groups, especially elderly patients, who can reduce the acceptance of this treatment. It is also advised to avoid using this mixture for patients with a history of urinary retention, stomach problems or eye pressure diseases. On the other hand, there may be a problem associated with half the life periods for each of the two pharmacorators, as “Truspium” has a half -sage of about 20 hours, while half the age of “adultery” is much shorter, only about 1.25 hours, and this gap in half life can cause a little deviations in relation to the balance of doses, and the effects of doses, and the effects of doses, and the effects of doses. The important availability of ‘adultery’ is also less than 1%, which means that it can reach the central nervous system more than the plasma, which explains its nerve effects, and in addition that ‘trocebium’ has central consequences, such as drowsiness, dizziness, hallucinations and confusion, which can cause the effects of the effects of the effects of the effects of the effects. However, studies show that the drug improves positive and negative symptoms of schizophrenia, which are symptoms that do not respond well to traditional treatments.